Allergan, Inc. – Company Information

0

Actavis acquired Allergan, Inc. on November 17, 2014 for $66 billion. 

Allergan, Inc., is an American multinational pharmaceutical company that focuses on developing and marketing medical devices, pharmaceuticals, and over-the-counter consumer products.

It is based in Irvine, California.

The company was founded in 1950 by Gavin S. Herbert – a pharmacist who created the first antihistamine eye drop in the US.

Allergan now has a team of 10,500 employees and a presence in more than 100 countries. It operates manufacturing plants in Waco, Texas; San Jose, Costa Rica; Westport, Ireland; and Bridgewater, New Jersey.

Its leading products include: Botox® (onabotulinumtoxinA) for the treatment of overactive bladder with symptoms of urinary incontinence, Restasis® (cyclosporine ophthalmic emulsion) for chronic dry eye due to inflammation, Lumigan® (bimatoprost ophthalmic solution), Botox® Cosmetic (onabotulinumtoxinA) aesthetic medical treatment, and Juvéderm® dermal fillers.

In 2014, Valeant Pharmaceuticals International Inc. teamed up with Pershing Square Capital Management to make a hostile bid for the Botox maker.

Overview

Allergan Logo


Allergan, Inc., Financial Results, Years Ended December 31

Operating data (in $ millions) 2014 2013
Product net sales $7,126.1 $6,197.5
Total revenues $7,237.9 $6,300.4
Cost of sales $842.4 $795.8
Selling, general and administrative costs $2,837.2 $2,519.4
Research and development $1,191.6 $1,042.3
Operating income $2,009.3 $1,809.3
Earnings from continuing operations $1,532.6 $1,272.5
Net earnings $1,528.8 $988.7
Net earnings attributable to Allergan, Inc. $1,524.2 $985.1
Balance sheet data (in $ millions)
Total assets $12,415.7 $10,574.3
Long-term debt $2,085.3 $2,098.3
Total stockholders’ equity $7,753.0 $6,463.2
Common share data (in $)
Basic earnings per share $5.12 $3.32
Diluted earnings per share $5.01 $3.26
Cash flow data (in $ millions)
Net cash provided by operating activities $1,927.8 $1,695.4
Net cash used for investing activities $182.7 $(1,375.3)
Net cash provided by (used for) financing activities $(204.0) $28.2
Cash and cash equivalents at beginning of year $3,046.1 $2,701.8
Cash and cash equivalents at end of year $4,911.4 $3,046.1

Financial Highlights Allergan

Source: “Allergan, Inc. Form 10-K 2014” 


You might also like More from author